DCGI recommends allowing Serum Institute to manufacture, stockpile QHPV vaccine

Published On 2022-07-08 12:00 GMT   |   Update On 2022-07-08 12:00 GMT
Advertisement

The Drugs Controller General of India has recommended allowing Serum Institute of India to manufacture and stockpile their life-saving qHPV vaccine against cervical cancer, official sources said on Wednesday. The recommendation has been sent to the Union Health Ministry which may issue a gazette notification shortly, they said.

Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, had written to the Health Ministry on February 4 seeking approval to manufacture and stockpile the qHPV vaccine as a priority for public health, to save time in making it and to ensure its early availability, an official source said.
Advertisement

For more details, check out the full story on the link below:

DCGI Recommends Allowing SII To Manufacture, Stockpile Life-Saving QHPV Vaccine Against Cervical Cancer


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News